FDA staff raises eye damage concerns for GSK's blood cancer drug

FDA staff reviewers have raised significant safety concerns regarding GSK's blood cancer drug Blenrep, citing potential eye damage (ocular toxicity) not observed with other multiple myeloma treatments, particularly when used in combination. This unique toxicity renders Blenrep's benefit-risk profile unclear, ahead of an independent expert meeting on Thursday. The development could impact the drug's commercial viability and GSK's oncology portfolio.

Analysis

U.S. Food and Drug Administration (FDA) staff reviewers have issued a significant warning regarding GSK's (GSK.L) blood cancer drug, Blenrep, highlighting concerns about its safety profile when used in combination therapies. The core issue is the drug's potential to cause ocular toxicity, a form of eye damage described as a "unique toxicity not seen with any currently available treatments for multiple myeloma." This specific adverse effect has led regulators to classify Blenrep's benefit-risk profile as "unclear," raising substantial doubts about its safety, tolerability, and appropriate dosage. The release of these briefing documents precedes a crucial meeting of the FDA's independent experts on Thursday, which will likely determine the drug's regulatory pathway and commercial viability. The strongly negative sentiment signal (-0.8 for GSK) underscores the market's perception of this heightened regulatory risk to a key asset in GSK's oncology portfolio.

Key Decisions for Investors

• Investors should closely monitor the outcome of the FDA's independent expert meeting on Thursday, as its recommendation will be a significant near-term catalyst for GSK's stock.
• The identified unique ocular toxicity presents a material risk to Blenrep's approval and market adoption, warranting a review of its potential contribution to GSK's future earnings.
• Given the FDA staff's explicitly negative stance on the drug's benefit-risk profile, holders of GSK may consider hedging or reducing their position ahead of the panel decision to mitigate downside risk.